Darunavir 600 And 800 Mg Tablet
Product Images NDC 69097-248

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Darunavir 600 And 800 Mg (NDC 69097-248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (4afcb3c7 F5a1 4c46 9955 970ad02fdecb 01)

Image (4afcb3c7 F5a1 4c46 9955 970ad02fdecb 01)
Chemical structure of darunavir, showing its detailed molecular framework including functional groups and stereochemistry, as well as the associated 2.5 H2O hydration state indicated.*
FDA Label Image

600mg (4afcb3c7 F5a1 4c46 9955 970ad02fdecb 06)

600mg (4afcb3c7 F5a1 4c46 9955 970ad02fdecb 06)
Label for Darunavir Tablets 600 mg oral tablets by Cipla USA Inc. The label shows the NDC 69097-248-03, a warning box about medicines that should not be taken with darunavir tablets, and storage instructions. Manufactured by Cipla Ltd., India, and packaged with 60 tablets, the label includes a barcode and space for batch overprinting of serial number, expiry, and lot information.*
FDA Label Image

800mg (4afcb3c7 F5a1 4c46 9955 970ad02fdecb 07)

800mg (4afcb3c7 F5a1 4c46 9955 970ad02fdecb 07)
Label for Darunavir Tablets 800 mg by Cipla USA Inc. The label indicates each film-coated tablet contains Darunavir Hydrate equivalent to 800 mg Darunavir. The package contains 30 tablets. Storage instructions, manufacturing details in India by Cipla Ltd., and a barcode are also shown. The label includes a warning to consult about medicines that should not be taken with Darunavir Tablets.*
FDA Label Image

Pk Results (Fig 02)

Pk Results (Fig 02)
Two side-by-side forest plots comparing pharmacokinetic parameters of Darunavir/ritonavir twice daily versus once daily dosing across second and third trimesters. Parameters include AUC total, Cmin total, AUC unbound, and Cmin unbound, with geometric mean ratios (GMR) and 90% confidence intervals shown graphically.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.